Role of hormonal therapy for prostate cancer: Perspective from Japanese experiences

Translational Andrology and Urology

Volumn 1, Issue 3, 2012, Pages 160-172

  Namiki, Mikio ^a   Ueno, Satoru ^a   Kitagawa, Yasuhide ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Adverse effects; Hormonal therapy; Prostate cancer

Indexed keywords

EID: 84875415383     PISSN: 22234683     EISSN: 22234691     Source Type: Journal    
DOI: 10.3978/j.issn.2223-4683.2012.07.03     Document Type: Review

References (67)

1. Huggins C, Hodges C. Studies on prostate cancer.1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
2. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173-81.
3. Green HJ, Pakenham KI, Headley BC, et al. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonalmedication of close monitoring. Psychooncology 2002;11:401-14.
4. Grant JD, Litwin MS, Lee SP, et al. Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study. J Urol 2011;185:1674-80.
5. Labrie F, Luu-The V, Liu SX, et al. The key role of 17ß-HSDs in sex steroid biology. Steroids 1997;62:148-58.
6. Mizokami A, Koh E, Fujita H, et al. The adrenal androgen, androstenediol, is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen recetor. Cancer Res 2004;64:765-71.
7. Narimoto K, Mizokami A, Izumi K, et al. Adrenal androgen levels as predictors of outcome in castrationresistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line antiandrogen. Int J Urol 2010;17:337-45.
8. Akaza H, Hinotsu S, Usami M. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009;115:3437-45.
9. Suzuki H, Okihara K, Miyake H. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180:921-7.
10. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:12-23.
11. Scholz M, Jennrich R, Strum S, et al. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 2005;173:1947-52.
12. Izumi K, Kadono Y, Shima T, et al. Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. Anticancer Res 2010;30:5201-5.
13. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
14. Namiki M, Kitamura M, Buczko E, et al. Rat testis P-450(17)alpha cDNA: the deduced amino acid sequence, expression and secondary structural configuration. Biochem Biophys Res Commun 1988;157:705-12.
15. Kitamura M, Buczko E, Dufau ML. Dissociation of hydroxylase and lyase activities by site-directed mutagenesis of the rat P45017 alpha. Mol Endocrinol 1991;5:1373-80.
16. Koh Y, Buczko E, Dufau ML. Requirement of phenylalanine 343 for the preferential ?4-lyase versus ?5-lyase activity of rat CYP17. J Biol Chem 1993;268:18267-71.
17. Attard G, Reid AHM, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8.
18. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone in patients in patients with docetaxel treated castrationresistant prostate cancer. J Clin Oncol 2010;28:1496-501.
19. Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res 2010;16:4319-24.
20. Soifer HS, Souleimanian N, Wu S, et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 2012;287:3777-87.
21. Tran C, Ouk S, Clegg NJ, et al. Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787.
22. Scher HI, Beer TM, Higano CS, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437.
23. Sun S, Sprenger CCT, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715-30.
24. Watson PA, ChenYF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. PNAS 2010;107:16759-65.
25. Yamashita S, Lai K, Chuang K, et al. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 2012;14:74-83.
26. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet 2009;373:301-08.
27. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
28. Bastian PJ, Gonzalgo ML, Aronson WJ, et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006;107:1265-72.
29. Zietman AL, Shipley WU. Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. Int J Radiat Oncol Biol Phys 1997;37:245-6.
30. Joon DL, Hasegawa M, Sikes C, et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997;38:1071-7.
31. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-6.
32. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7.
33. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
34. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360:2516-27.
35. Souhami L, Bae K, Pilepich M, et al. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 2009;27:2137-43.
36. Horwitz EM, Bae K, Hanks GE, et al. Ten-year followup of radiation therapy oncology group protocol 92- 02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-504.
37. Stock RG, Cahlon O, Cesaretti JA, et al. Combined modality treatment in the management of highrisk prostate cancer. Int J Radiat Oncol Biol Phys 2004;59:1352-9.
38. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-99.
39. Konaka H, Egawa S, Saito S, et al. Tri-modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormonal therapy for highrisk localized prostate cancer (TRIP): study protcol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 2012;12:110.
40. Messing EM, Manola J, Yao J. Immediate versus deferred androgen deprivation treatment in patients with nodepositive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-9.
41. Bittner N, Merrick GS, Wallner KE, et al. Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer. Oncology (Williston Park) 2008;22:995-1004; discussion 1006, 1011-7.
42. Dorff TB, Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 Study. J Clin Oncol 2011;29:2040-5.
43. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005;12:46-61.
44. Maeda O. Option and indication for early stage prostate cancer. Jap J Cancer Chemother 2003;30:26-31.
45. Fukagai T, Namiki TS, Carlile RG, et al. Comparison of clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006;97:1190-3.
46. Akaza H, Homma Y, Usami M, et al. Prostate Cancer Study Group. Efficacy of primary hormonal therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int 2006;98:573-9.
47. Egawa M, Misaki T, Imao T, et al. Retrospective study on stage B prostate cancer in the Hokuriku District, Japan. Int J Urol 2004;11:304-9.
48. Kitagawa Y, Koshida K, Mizokami A, et al. Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. Int J Urol 2003;10:377-82.
49. Schulman CC, Debruyne FM, Forster G, et al. 4-yearfollow- up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol 2000;38:706-13.
50. Labrie F, Candas B, Gomez JL, et al. Can combined androgen blockade provide long-term control or piossible cure of localized prostate cancer? Urology 2002;60:115-19.
51. Ueno S, Namiki M, Fukagai T, et al. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol 2006;13:1494-500.
52. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
53. Labrie F, Bélanger A, Luu-The V, et al. Gonadotropinreleasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005;26:361-79.
54. Cooperberg MR, Grossfeld GD, Lubeck DP, et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-9.
55. Tanaka N, Hara H, Yamabe F, et al. Investigation on prostate re-biopsy and high-sensitivity PSA of prostate cancer patients receiving endocrine therapy. Jap J Urol 2005;96:196.
56. Akakura K, Ito H, Sato N. Intermittent androgen suppression for prostate cancer. Nippon Rinsho 2000;58:289-91.
57. Mizokami A, Ueno S, Fukagai T, et al. Global update on defining and treating high-risk localizing prostate cancer with leuprolin: an Asian perspective. BJU Int 2007;99:6-9.
58. Kato T, Komiya A, Suzuki H, et al. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Int J Urol 2007;14:416-21 59
59. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56
60. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-5.
61. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG85-01. J Clin Oncol 2009;27:92-9.
62. Akaza H. Future prospects for luteinizing-hormonereleasing hormone analogues in prostate cancer treatment. Pharmacology 2010;85:110-20.
63. Izumi K, Mizokami A, Sugimoto K, et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 2009;73:1342-6.
64. Basaria S, Muller DC, Carducci MA, et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006;106:581-8.
65. Hoffman RM, Hunt WC, Gilliland FD, et al. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer 2003;97:1653-62.
66. Namiki M, Mizokami A, Akaza H. Should patients with localized prostate cancer receive primary androgen deprivation therapy? Nat Clin Pract Urol 2008;5:648-9.
67. Min L, Yanase T, Tanaka T, et al. A novel synthetic androgen receptor ligand, S42, works as a selective androgen receptor modulator and possesses metabolic effects with little impact on the prostate. Endocrinology 2009;150:5606-16.